Table 1.
Characteristics of patients with or without loco-regional recurrence and distant metastasis after resection for clinical stage I NSCLC
| |
Locoregional recurrence |
Distant metastasis |
||||
|---|---|---|---|---|---|---|
| No ( n = 244) (100%) | Yes ( n = 17) (100%) | p -value a | No ( n = 241) (100%) | Yes ( n = 20) (100%) | p -value a | |
| Sex: |
|
|
|
|
|
|
|
Male |
110 (45.08) |
7 (41.18) |
0.806 |
108 (44.81) |
9 (45) |
0.989 |
|
Female |
134 (54.92) |
10 (58.82) |
|
133 (55.19) |
11 (55) |
|
| Histopathology: |
|
|
|
|
|
|
|
Adenocarcinoma |
209 (85.66) |
17 (100) |
0.140 |
210 (87.14) |
16 (80) |
0.322 |
|
Other |
35 (14.34) |
0 (0) |
|
31 (12.86) |
4 (20) |
|
| Differentiation: |
|
|
|
|
|
|
|
Well |
98 (40.16) |
4 (23.53) |
|
99 (41.08) |
3 (15) |
|
|
Moderate |
97 (39.75) |
5 (29.41) |
0.032
|
93 (38.59) |
9 (45) |
0.035
|
|
Poor |
49 (20.08) |
8 (47.06) |
|
49 (20.33) |
8 (40) |
|
| Location: |
|
|
|
|
|
|
|
Central |
125 (51.23) |
11 (64.71) |
0.324 |
124 (51.45) |
12 (60) |
0.494 |
|
Peripheral |
119 (48.77) |
6 (35.29) |
|
117 (48.55) |
8 (40) |
|
| Adjuvant chemotherapy: |
|
|
|
|
|
|
|
Yes |
89 (36.48) |
8 (47.06) |
0.440 |
80 (33.2) |
3 (15) |
< 0.001
|
|
No |
155 (63.52) |
9 (52.94) |
|
161 (66.8) |
17 (85) |
|
| LVSI: |
|
|
|
|
|
|
|
Absent |
222 (90.98) |
14 (82.35) |
0.214 |
221 (91.7) |
15 (75) |
0.031
|
|
Present |
22 (9.02) |
3 (17.65) |
|
20 (8.3) |
5 (25) |
|
| Operation: |
|
|
|
|
|
|
|
Lobectomy |
228 (93.44) |
17 (100) |
0.609 |
225 (93.36) |
20 (100) |
0.620 |
|
Wedge |
16 (6.56) |
0 (0) |
|
16 (6.64) |
0 (0) |
|
| p-stage: |
|
|
|
|
|
|
|
I |
169 (69.26) |
10 (58.82) |
0.002
|
168 (69.71) |
11 (55) |
0.232 |
|
II |
44 (18.03) |
3 (17.65) |
|
40 (16.60) |
7 (35) |
|
|
III |
31 (12.71) |
3 (17.65) |
|
32 (13.28) |
2 (10) |
|
| IV | 0 (0) | 1 (5.88) | 1 (0.41) | 0 (0) | ||
aSignificance was assessed using χ2 tests. Key: SCC, squamous cell carcinoma; LVSI, lymphovascular space invasion; p-stage, pathology stage.
Statistically significant p values are depicted in underline.